MENLO PARK, Calif. and GREENWICH, Conn., Feb. 16, 2017 /PRNewswire/ -- Longitude Capital, a private investment firm focused on venture growth investments in biotechnology and medical technology, today announced the promotion of Josh Richardson, M.D. to Managing Director.
Dr. Richardson focuses on investments in biotechnology companies. He is a board observer at InfaCare Pharmaceutical Corporation, and has played important roles in Longitude's investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence Pharmaceuticals (acquired by Mallinckrodt), Collegium Pharmaceutical, and Precision Dermatology (acquired by Valeant Pharmaceuticals).
Dr. Richardson originally joined Longitude Capital in 2011 from McKinsey & Company where he was an Engagement Manager. From 2014 to early 2016, Dr. Richardson was a Public Equities Analyst at HealthCor Management where he managed small and mid-cap biotechnology investments. In 2016, Dr. Richardson re-joined Longitude Capital.
Longitude Capital also added several Vice Presidents to the investment staff in 2016. Maxwell Bikoff focuses on investments in medical technology and joins the firm from Cardinal Health, where he held a series of strategy, finance, and operating roles and was most recently the Director of North America Marketing for the Cordis cardiovascular franchise. Christina Ghenoiu, Ph.D. focuses on investments in biotechnology and was previously in Biotechnology Equity Research at Cowen and Company, where she covered large and small/mid-cap biotechnology companies. Allyson Rinderle focuses on biotechnology investments and previously worked at Aisling Capital and in J.P. Morgan's Healthcare Investment Banking practice. Finally, Michael Wert, who worked at Longitude Capital from 2008 to 2012, re-joins the firm's medical technology practice from Warburg Pincus. All four operate out of the firm's Menlo Park, California office.
Managing Director and co-Founder Patrick Enright stated, "Josh's experience and expertise underscore our commitment to executing a venture growth strategy in life sciences rooted in building a balanced portfolio of clinical stage and commercial-stage companies that can generate attractive expected returns within three to five years. We are proud of all that he has accomplished and we look forward to his continued success as an investor and partner, as well as a mentor to our outstanding group of Vice Presidents."
About Longitude Capital
Longitude Capital is a private investment firm that makes venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. Longitude Capital invests in both privately held and publicly traded life science companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over $1.2 billion across three funds and has offices in Menlo Park, CA and Greenwich, CT. For more information, please visit www.longitudecapital.com.
Contact Longitude Capital: Michaela Parnell 650-854-5700 [email protected]
Advertisement
Dr. Richardson focuses on investments in biotechnology companies. He is a board observer at InfaCare Pharmaceutical Corporation, and has played important roles in Longitude's investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence Pharmaceuticals (acquired by Mallinckrodt), Collegium Pharmaceutical, and Precision Dermatology (acquired by Valeant Pharmaceuticals).
Advertisement
Dr. Richardson originally joined Longitude Capital in 2011 from McKinsey & Company where he was an Engagement Manager. From 2014 to early 2016, Dr. Richardson was a Public Equities Analyst at HealthCor Management where he managed small and mid-cap biotechnology investments. In 2016, Dr. Richardson re-joined Longitude Capital.
Longitude Capital also added several Vice Presidents to the investment staff in 2016. Maxwell Bikoff focuses on investments in medical technology and joins the firm from Cardinal Health, where he held a series of strategy, finance, and operating roles and was most recently the Director of North America Marketing for the Cordis cardiovascular franchise. Christina Ghenoiu, Ph.D. focuses on investments in biotechnology and was previously in Biotechnology Equity Research at Cowen and Company, where she covered large and small/mid-cap biotechnology companies. Allyson Rinderle focuses on biotechnology investments and previously worked at Aisling Capital and in J.P. Morgan's Healthcare Investment Banking practice. Finally, Michael Wert, who worked at Longitude Capital from 2008 to 2012, re-joins the firm's medical technology practice from Warburg Pincus. All four operate out of the firm's Menlo Park, California office.
Managing Director and co-Founder Patrick Enright stated, "Josh's experience and expertise underscore our commitment to executing a venture growth strategy in life sciences rooted in building a balanced portfolio of clinical stage and commercial-stage companies that can generate attractive expected returns within three to five years. We are proud of all that he has accomplished and we look forward to his continued success as an investor and partner, as well as a mentor to our outstanding group of Vice Presidents."
About Longitude Capital
Longitude Capital is a private investment firm that makes venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. Longitude Capital invests in both privately held and publicly traded life science companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over $1.2 billion across three funds and has offices in Menlo Park, CA and Greenwich, CT. For more information, please visit www.longitudecapital.com.
Contact Longitude Capital: Michaela Parnell 650-854-5700 [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/longitude-capital-promotes-josh-richardson-md-to-managing-director-300408938.html
SOURCE Longitude Capital
